Business Wire

TAKEDA-PHARMACEUTICAL

11.6.2020 08:02:10 CEST | Business Wire | Press release

Share
Takeda Selects Two New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Support Strong Health Systems and Access to Healthcare in Developing Countries

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK ) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Responsibility (CSR) Program, which makes long-term commitments to strengthen healthcare systems and improve access to healthcare for all in developing countries. As part of an annual decision-making process, Takeda employees worldwide have voted to add the Access to Health Fund and Bridges to Development as new partners for the Global CSR Program , which now supports 16 programs in more than 60 countries.

Takeda’s commitments to these new partner organizations in FY2020 include:

  • JPY 1.1 billion (USD 10.1 million*) to Access to Health Fund to help build and improve community health centers and empower health staff from ethnic health organizations and ethnic community-based health organizations (EHOs/ECBHOs) in Myanmar’s Shan State to deliver quality health services, particularly for mothers and children, over the next 5 years.
  • JPY 681 million (USD 6.3 million* ) to Bridges to Development to eliminate or control 5 neglected tropical diseases in Papua New Guinea and Vanuatu including lymphatic filariasis, yaws, leprosy, trachoma, and soil-transmitted helminthiases. The 3-year project will improve health worker capacity, access to care and treatment.

“We welcome and very much value the interest that Takeda and its employees have shown in contributing to improving the health of vulnerable populations in conflict-affected and hard-to-reach areas in Shan State in Myanmar,” said Oren Ginzburg, Access to Health Fund Director.

“The Bridges team is thrilled to embark on this important work in service of communities and populations that have been frequently left behind,” said Julie Jacobson, Managing Partner & Co-Founder of Bridges to Development. “In this project, working with countries, we aim to achieve lasting health benefits through the elimination and control of several neglected tropical diseases in one innovative approach. We are thankful to Takeda employees who helped make this possible with their support.”

This year represents the 5th anniversary of Takeda’s Global CSR Program, which empowers employees in Takeda’s 80 countries of operation to be the decisionmakers for which innovative, high-impact activities receive the Company’s support. The Program, rooted in the company’s values , actively partners with world-class organizations and nongovernmental organizations (NGOs) with proven track records of addressing global health problems in effective, enduring ways to prevent disease, train health workers, strengthen supply chains, and improve access to quality diagnosis and treatment for patients worldwide.

“Since its launch in 2016, Takeda’s Global CSR Program has focused on initiatives that strengthen health systems and increase access across the patient journey in low- and middle-income countries. We’re expecting to reach at least 17 million beneficiaries through 2025 globally” said Takako Ohyabu, Chief Global Corporate Affairs Officer. “We are proud to partner with the Access to Health Fund and Bridges to Development as we strive to increase health worker capacity and preventive care for patients everywhere, ensure reliable access to essential equipment and supplies, and empower communities with knowledge, services, and access to care."

In less than five years, Takeda’s Global CSR Program partners have delivered transformational impact that serves communities worldwide today and will continue to contribute to better health outcomes and stronger health systems for years to come, including:

  • JOICFP, Plan International, and UNICEF reached nearly 700,000 pregnant women and mothers, newborns, children, and adolescents, with quality health care, services, and education in sub-Saharan Africa and the Middle East.
  • JOICFP, Plan International, Seed Global Health, and UNICEF in Africa and the Middle East, with World Vision in South Asia, have collectively trained approximately 6,000 health workers in 15 countries, including qualified nurses, midwives, and physician trainees, as well as community health workers and nutrition volunteers.
  • Millions of children have been immunized against measles, and the capacity of trainings offered by academic and clinical institutions in sub-Saharan Africa has been expanded exponentially.

In line with Takeda’s core values and longstanding support for strong health systems and access to healthcare for all, Takeda recently announced contributions to the global COVID-19 response through three United Nations-led organizations to strengthen health systems, improve access to care and supplies, and address food insecurity.

Takeda also forges farsighted public-private philanthropic partnerships with game-changing multilateral and academic institutions worldwide, such as with The Global Fund to Fight AIDS, Tuberculosis and Malaria , and the London School of Hygiene & Tropical Medicine .

* Financial information relating to the donations has been converted from JPY to USD using the ¥108.87:$1 as of June 3, 2020. For the avoidance of doubt, the amounts payable as part of the donations are denominated in JPY.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye